How would you treat a patient with EGFR+ oligo-metastatic lung adenocarcinoma status post resection of the primary and metastatic sites?  

This is a somewhat challenging question - on the one hand, the patient has metastatic (albeit "oligo" metastatic) cancer and systemic treatment with osimertinib is clearly indicated and appropriate for metastatic EGFR mutant lung cancers. On the other hand, all known disease has been resected, and t...